한국응용과학기술학회지 (Journal of the Korean Applied Science and Technology)

  • 제26권1호
  • /
  • Pages.29-37
  • /
  • 2009
  • /
  • 1225-9098(pISSN)
  • /
  • 2288-1069(eISSN)
한국응용과학기술학회 (The Korean Society of Applied Science and Technology)
권호 표지
DOI QR코드

DOI QR Code

Synthesis of a New 4-(Pyridin-3-yl)pyrimidine Derivatives for Anticancer Activity

  • Jung, Se-Jin (Life Sciences Research Division, Korea Institute of Science and Technology) ;
  • El-Deeb, Ibrahim Mustafa (Department of Biomolecular Science, University of Science and Technology) ;
  • Lee, So-Ha (Life Sciences Research Division, Korea Institute of Science and Technology)
  • 발행 : 2009.03.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This study is focused on the synthesis of urea and amide derivatives particularly, since the amide moiety is an essential binding group at the binding site. Urea derivatives 3-7 and 13-14 were obtained by reaction of 2-aminopyrimidines and other amines with diverse isocyanates in pyridine as a solvent under reflux. The urea derivatives were obtained in low yield because of the highly electron deficient nature of the amino group of the 2-aminopyrimidine. Amide derivatives 8-10 were obtained in moderate yields by reaction of compound 1 with aryl chloride derivatives. Also, arylamine 11 was synthesized by Buchwald-Hartwig amination in moderate yields. Most of the compound did not show good activity against A375P melanoma cells, compared with Sorafenib as control compound.

키워드

참고문헌

  1. G. Manning, D. B. Whyte, R. Martinez,T. Hunter, and S. Sudarsanam, Theprotein kinase complement of the humangenome, Science, 298, 1912 (2002) https://doi.org/10.1126/science.1075762
  2. M. A. Pearson and D. Fabbro, Targetingprotein kinases in cancer therapy: asuccess?, Expert Rev. Anticancer Ther.,4, 1113 (2004) https://doi.org/10.1586/14737140.4.6.1113
  3. S. Klein and A. Levitzki, Signaltransduction therapy for cancer - whithernow?, Curro Signal Transduction Ther., 1,1 (2006) https://doi.org/10.2174/157436206775269244
  4. S. S. Sridhar, D. Hedley, and L. L. Siu,Raf kinase as a target for anticancertherapeutics, Mol. Cancer Ther., 4, 677(2005) https://doi.org/10.1158/1535-7163.MCT-04-0297
  5. J. Klysik, S. j. Theroux, j. M. Sedivy, j.S. Moffit, and K. Boekelheide, Signalingcrossroads: The function of Raf kinaseinhibitory protein in cancer, the centralnervous system and reproduction. Cell.Signalling, 20, 1 (2008) https://doi.org/10.1016/j.cellsig.2007.07.003
  6. X. Xu, R. M. Quiros, P. Gattuso, K. B.Ain, and R. A. Prinz, High prevalence ofb-RAF gene mutation in papillary thyroidcarcinomas and thyroid tumor cell lines.Cancer Res., 63, 4561 (2003)
  7. I. Niculescu-Duvaz, E. Roman, ES. R.Whittaker, R. Kirk, I. j. Scanlon, L. C.Davies, D. Niculescu-Duvaz, R Marais,and C. J. Springer, Novel inhibitors ofB-RAF based on a disubstituted pyrazinescaffold. generation of a nanomolar lead.J Med. Chem, 49, 407 (2006) https://doi.org/10.1021/jm050983g
  8. J. Zimmermann, E. Buchdunger, H. Mett,T. Meyer, N. B. Lydon, and P. Traxler,Phenylarnino-pyrirnidine (P AP)derivatives:a new class of potent andhighly selective PDGF -receptorautophosphorylation inhibitors, Bioorg.Med Chem Lett, 6, 1221 (1996) https://doi.org/10.1016/0960-894X(96)00197-7
  9. A. A. San Juan, StructUral. investigationof PAP derivatives by CoMFA andCoMSIA reveals novel insight towardsinhibition of Bcr-Abl oncoprotein, J Mol.Graphics Modell. 26, 482 (2007) https://doi.org/10.1016/j.jmgm.2007.03.001
  10. I. Collins and P. Workman, Design anddevelopment of signal transductioninhibitors for cancer treatment: experienceand challenges with kinase targets. CurroSignal Transduction Ther., 1, 13 (2006)
  11. E. Weisberg, P. Manely, j. Mestan, S.Cowan-Jacob, A. Ray, and j. D. Griffin,AMN107 (nilotinib): a novel and selectiveinhibitor of BCR-ABL. Br. J Cancer, 94,1765 (2006) https://doi.org/10.1038/sj.bjc.6603170
  12. H. Adams, S. R. Batten, G. M. Davies,M. B. Duriska, j. C. Jeffery, P. Jensen, j.Lu, G. R. Motson, S. j. Coles, M. B.Hursthouse, and M. D. Ward, New bis-,tris- and tetrakis(pyrazolyI)borate ligandswith 3-pyridyl and 4-pyridyl substituents:synthesis and coordination chemistry.Dalton Trans., 11, 1910 (1910)
  13. W.-S. Huang and W. C. An efficientsynthesis of nilotinib (AMN107).Shakespeare, Synthesis, 14, 2121 (2007)
  14. I. M. EI-Deeb, j. C. Ryu, and S. H. Lee,Synthesis of New N-arylpyrirnidin-2-amine derivatives using a palladiumcatalyst, Molecules, 13, 818 (2008) https://doi.org/10.3390/molecules13040818
  15. S. M. Wilhelm, C.; Carter, L. Tang, D.Wilkie, A. McNabola, H. Rong, C. Chen,X. Zhang, P. Vincent, M. McHugh, Y.Cao, j. Shujath, S. Gawlak, D. Eveleigh,B. Rowley, L. Liu, L. Adnane, M. Lynch,D. Auclair, I. Taylor, R. Gedrich, A.Voznesensky, B. Riedl, L. E. Post, G.Bollag, and P. A. Trail, BAY 43-9006exhibits broad spectrum oral antitumoractivity and targets the RAF !MEK!ERKpathway and receptor tyrosine kinasesinvolved in tumor progression andangiogenesis, Cancer Res., 64, 7099 (2004) https://doi.org/10.1158/0008-5472.CAN-04-1443